Melanotan II tanning claims: what the science actually shows

What did @flexxystreamz actually say?

The creator posted a before-and-after tan and told viewers that Melanotan II (MT-2) at "250 micrograms once a week" is responsible for dramatic skin darkening. They acknowledged being Hispanic and said that may speed up results, noted "a little bit of nausea at the beginning," and warned that the peptide "will enhance your beauty marks and freckles." Their verdict: "it's pretty worth it."

What they did not mention: MT-2 is not approved by the FDA for any use, is not legal to sell as a human therapeutic in the United States, and carries a risk profile that goes well beyond transient nausea. The casual framing, the selfie-style delivery, and the nearly one million views make this worth examining carefully.

Does the science back this up?

Yes, MT-2 does produce skin darkening, and the mechanism is real. But the science also comes with serious warnings that the creator skipped entirely.

MT-2 is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It binds melanocortin receptors, primarily MC1R and MC4R, triggering melanin synthesis. Skin darkening is a documented pharmacological effect. Hadley and Dorr (2006, Peptides) confirmed the tanning effect in early human studies. That part checks out.

The MC4R activity, however, is where the safety story gets complicated. MC4R signaling is associated with sexual arousal, appetite suppression, nausea, and cardiovascular effects including increased blood pressure and spontaneous erections in male subjects. Dorr et al. (1996, Journal of Clinical Endocrinology and Metabolism) documented these effects even at low doses in a controlled setting. The nausea the creator casually mentions is a central nervous system effect, not a local injection reaction.

More seriously, multiple case reports and dermatology literature have flagged MT-2 use as a possible trigger for dysplastic nevus changes. Cooke et al. (2012, British Journal of Dermatology) documented melanocytic lesion changes in users, which raises real concern about melanoma risk in susceptible individuals.

What did they get wrong (or right)?

Credit where it is due: the creator was honest that results vary by baseline skin tone, telling viewers they are Hispanic and may darken faster. That is physiologically accurate. People with more baseline melanin and active MC1R variants do respond more strongly to melanocortin stimulation.

They also correctly flagged nausea as a side effect. That is real and documented.

But here is what they got wrong or omitted entirely. First, they presented a specific dose, "250 micrograms once a week," as if it is a safe or standard protocol. There is no FDA-approved dose because MT-2 has no approved use. Sharing a number like that in a video seen by nearly one million people functions as de facto dosing advice, and it should not.

Second, they said nothing about nevus changes. If you have moles, MT-2 can cause them to darken, grow, or change in ways that require a dermatologist to evaluate. The creator mentioned freckles but framed it cosmetically. That framing is misleading given the published dermatology literature.

Third, no mention of cardiovascular effects, priapism risk in males, or the fact that the product is not legal for human use in the U.S.

What should you actually know?

MT-2 is not a tanning bed upgrade. It is an unregulated synthetic peptide with systemic effects that go beyond skin color.

The FDA has issued warnings about Melanotan products sold online. The products are not approved, manufacturing quality is uncontrolled, and contamination risks are real. The British Medicines and Healthcare products Regulatory Agency (MHRA) issued similar warnings in 2012 after a cluster of adverse event reports.

The nevus risk deserves specific attention. If you use MT-2 and have existing moles or atypical nevi, you need a full skin check before and after. The Cooke et al. (2012) case series is not a fringe concern. It is published, peer-reviewed dermatology literature describing real patients with real lesion changes.

The nausea the creator shrugged off as a minor startup issue is a signal that the peptide is crossing the blood-brain barrier and activating central melanocortin receptors. That is a systemic pharmacological effect, not a sore injection site.

If you are exploring peptide therapy for any reason, that conversation belongs with a licensed clinician who can review your health history, not a TikTok comment section.